Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M

OMEROS CORP

Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.
Omeros ended 2022 with ~$195M cash; combined with $200M milestone provides funding into at least 2025.
2022 U.S. net sales of OMIDRIA totaled $131M; CAA 2023 secures separate payment for non-opioid pain drugs through Jan 2028.
Proceeds to fund R&D, manufacturing, potential acquisitions; may retire convertible notes.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

OMEROS CORP reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

U.S. net sales of OMIDRIA in 2022 totaled $131 million.

View on SEC.gov

Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-000894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.